On the stock market since 2021, it operates in the world of health and science. It has 5,000 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 9% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $319.6M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 71% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 9% a year on average.
There is $867.7M in the vault; even if every debt were paid off, $319.6M would remain.
It pays out $0.03 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
On our five-subject report card, AMBBY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AMBBY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.